---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-200256"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:24:30.753329+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Invivyd reports Q2 2024 net product revenue of $2.3M, expects 2024 revenue of $150-200M

## Summary
- PEMGARDA launched commercially in Q2 2024 with $2.3M net product revenue; early Q3 commercial acceleration noted.
- Cash and cash equivalents were $147.9M as of June 30, 2024; projected year-end cash at least $75M.
- EUA amendment request submitted to FDA for PEMGARDA for treatment of mild-to-moderate COVID-19 in immunocompromised patients.
- Next-generation molecule VYD2311 first-in-human trial dosing scheduled to begin late August 2024.
- Tim Lee joined as Chief Commercial Officer; board expanded with Srishti Gupta and Kevin F. McLaughlin.

## SEC filing metadata
- accession: 0001193125-24-200256
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312524200256/0001193125-24-200256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312524200256/d878899d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-200256
- JSON: https://secwatch.observer/filing/0001193125-24-200256.json
- Plain text: https://secwatch.observer/filing/0001193125-24-200256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.